Cantor Fitzgerald maintains Amgen stock rating ahead of earnings

Amgen reported a positive Phase 3 subcutaneous TEPEZZA result with a 77% proptosis response vs 19.6% for placebo, released ahead of schedule, which should materially improve the product outlook. Cantor Fitzgerald kept a Neutral rating with a $350 price target (P/E 23.85, PEG 0.27) and views the Apr 30 Q1 2026 print as a favorable setup with expected commercial beats on Repatha, Uplizna, Krystexxa and Imdelltra; potential negatives include MariTide updates or IRS tax litigation. William Blair and RBC reiterated Outperforms on Amgen; Amgen's strong trial results also disadvantaged Viridian relative to its elegrobart program, though Stifel maintained a $48 target on Viridian.

Analysis

A major biologics player’s recent program progress creates an asymmetric commercial payoff that the market is under-discounting: easier-to-administer formulations shift margin capture to the manufacturer, reduce per-patient administration friction, and can expand the addressable treated population by an estimated 20–30% in the first 12–24 months if payers accept outpatient use. That flow-through benefits upstream suppliers (SC delivery systems, contract-fill/finish) and squeezes competitors that rely on IV-only dynamics or premium pricing, forcing faster lifecycle decisions and likely accelerating M&A interest in smaller niche competitors.

Key near-term catalysts are commercial-readout datapoints (real-world uptake, payer coverage decisions, and early safety signals) over the next 3–12 months; legal/tax litigation or late-stage pipeline binaries are multi-quarter tail risks that could erase valuation tailwinds if unfavorable. Manufacturing scale and reimbursement pushback are plausible chokepoints — a 6–18 month capacity shortfall would lift selected CMO names but cap the parent’s multiple until supply normalizes.

Consensus positioning appears to underweight durable margin and market-share upside while overestimating competitor survivability; that creates a clear asymmetric trade set-up. Execution sensitivity argues for option structures or hedged equity exposure sized to commercialization milestones (coverage decisions, initial real-world prescribing trends). Monitor prescription/HCPCS flow, payer bulletin activity, and any litigation filings as 1–3 month binary triggers to re-rate positions.

Key Decisions for Investors

• Buy AMGN 6-month call spread: long ATM+10% / short ATM+35%, size 1–2% NAV. Rationale: asymmetric upside to commercialization news with limited premium outlay; target 2.5x payoff on a 20–30% stock move, max loss = premium paid.
• Pair trade (directional): long AMGN equity 1% NAV / short VRDN equity 0.5% NAV for 6–12 months. Rationale: hedge sector risk while expressing relative winner/loser; unwind if pair diverges >30% or after two consecutive quarters of outperformance undercutting VRDN’s pipeline thesis.
• Speculative hedge: buy VRDN 3–6 month puts (delta ~0.25), size 0.25% NAV. Rationale: low-cost asymmetry to protect vs competitive displacement or adverse early commercial datapoints; max loss = premium, target 3–5x if downside materializes.
• Tactical watchlist & triggers: accumulate CMO/SC-device exposure on evidence of supply tightness (monitor order fills, capacity announcements) — enter on a confirmed 5%+ sell-off in parent while supply metrics show stress; set strict stop at 25% adverse move or upon resolution of the supply bottleneck.